Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06147830 · ClinicalTrials.gov registry record
A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 2,202
- Enrollment target
NCT06147830: Completed study, sponsored by AstraZeneca.
NCT06147830 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 2,202 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06147830 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 2,202 participants
- Enrollment target
Study Summary
REVERXaL study aims to increase the understanding of the patient characteristics, bleeding presentation, health care interventions provided, and the clinical as well as self-reported health outcomes of patients with major bleeding in the presence of Factor Xa inhibitor treatment. The generation of insight on treatment approaches and associated outcomes in hospitalized patients with Factor Xa inhibitor-related major bleeds may inform clinical guidelines, health system decision making and streamline treatment pathways in this population.
Primary Outcome
Summary statistics will be used to describe demographics.
Interventions
- OTHER None (Observational study)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,202 participants |
| Start Date | 2023-12-04 |
| Est. Completion | 2024-11-30 |
What the finished NCT06147830 record still lists
NCT06147830 is an observational study that tracks outcomes without assigning an intervention. Its 2,202 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which None (Observational study) is the first listed.
NCT06147830 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06147830 about?
NCT06147830 is a clinical study titled "A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment". REVERXaL study aims to increase the understanding of the patient characteristics, bleeding presentation, health care interventions provided, and the clinical as well as self-reported health outcomes of patients with major bleeding in the presence of Factor Xa inhibitor treatment. The generation of i...
What is the current status of trial NCT06147830?
This trial is currently completed. The enrollment target is 2,202 participants. The study started on 2023-12-04. Estimated completion is 2024-11-30.
What interventions are being tested in trial NCT06147830?
The interventions under investigation include: None (Observational study) (OTHER).
Who is sponsoring clinical trial NCT06147830?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
- NCT06526988 · 2,200 participants · NA
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
- NCT06682650 · 2,200 participants · NA
Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI